This finding suggests a possible multi‐target approach of addressing HCC pathology and activating SIRT5 activity, for example, through membrane‐permeable succinate to bypass the failure of producing succinate in the TCA cycle. Here, SIRT5 is linked to hepatocellular carcinoma.